LataMed AI Corp is a technology company focused on the development and deployment of artificial intelligence-driven healthcare solutions across Latin America... Show more
LataMed AI Corp. is a development-stage healthcare technology company building digital health infrastructure, telehealth capabilities, care-coordination tools, and AI-supported medical solutions for Latin America. Incorporated in 2008 and based in Caracas, Venezuela, the company was formerly known as Catalyst Crew Technologies Corp. and adopted the LataMed AI name in April 2026, with its OTC ticker changing from LMEDD to LMED.
The company's strategy centers on a telemedicine ecosystem designed to connect patients, medical professionals, pharmacies, insurers, payment providers, and other participants in the healthcare system. It is also developing a suite of AI-assisted clinical platforms — CardioAI, PulmoAI, and NeuroAI — intended to support cardiovascular, pulmonary, and neurological evaluation. Because the business is still in its development phase, it generates little operating revenue and has relied on strategic agreements to establish an early foothold in emerging markets.
Over the last 30 days, LMED shares declined by roughly 85%, falling from a range of approximately $0.31 to $0.47 to around $0.05. The stock recorded a 52-week low of $0.0511 on September 30, 2026, against a 52-week high of $1.38. The move reflects both a genuine erosion in share value and the extremely thin liquidity typical of micro-cap OTC securities.
The quarterly picture is even steeper. Over the last three months, the stock has fallen approximately 88%, continuing a longer pattern of decline from earlier-year levels. The persistent downward trend has occurred even as management announced a series of commercial and governmental collaborations, underscoring that market participants remain focused on the company's lack of revenue and rising losses rather than its pipeline of announced initiatives.
Several verified factors shaped the sharp decline. The company's 5-for-1 forward stock split and mandatory share exchange, implemented alongside a new CUSIP in mid-2026, mechanically reduced the nominal per-share price and added complexity for existing holders. While a forward split does not by itself change a company's market value, the accompanying restructuring and resale registration of shares held by certain insiders and employees added supply-side pressure on a thinly traded stock.
Fundamentals also weighed on sentiment. LataMed AI reported a widening net loss in its second quarter of 2026, and its six-month loss expanded year over year. With minimal revenue and an accumulated deficit, the company has continued to depend on capital-raising activity, which can dilute existing shareholders. Combined with low average daily trading volumes and negative price momentum, these factors created an environment in which selling pressure outpaced any positive news flow.
The broader multi-month trend reflects a development-stage company undergoing significant corporate restructuring while still searching for a sustainable commercial model. Over the past quarter, the company executed a name change, a ticker change, a forward stock split, and a mandatory share exchange — a series of administrative changes that can disorient retail investors and reduce confidence in a micro-cap name.
During the same period, management announced multiple collaborations, including a telecom alliance in Venezuela, agreements to develop AI and automation tools for pharmaceutical workflows, and a cooperation agreement with Venezuela's science and health ministries for a deployment in La Guaira. However, these initiatives remain early-stage and subject to implementation, regulatory, and funding conditions. As a result, the announcements have not offset concerns about the company's limited revenue and ongoing losses, and the stock has continued to trade lower.
For traders seeking a more data-driven approach, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only top-performing and most relevant bots are surfaced in this section. The featured bots differ in strategy, timeframe, and performance metrics, giving users a way to compare approaches rather than relying on a single model. Browsing the page can help investors explore how algorithmic strategies are positioned across current market conditions.
Investors following LataMed AI should monitor whether announced partnerships and the planned mobile healthcare application translate into actual deployments and revenue. The completion and commercial rollout of the company's mobile app, the execution of the La Guaira public-health initiative, and any progress on its CardioAI, PulmoAI, and NeuroAI platforms are key operational milestones. Equally important are the company's cash position, its reliance on capital-raising, and the pace of its net losses, all of which will shape its ability to fund operations without further dilution.
Given the stock's low liquidity and extreme volatility, price swings can be amplified by relatively small order flows. Regulatory and execution risk in emerging markets, along with the company's development-stage status, remain central considerations. This is not financial advice, and investors should weigh these risks against their own objectives before making any decisions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PackagedSoftware